Premium
New prolyl 4‐hydroxylase inhibitor reduces procollagen gene expression and enzyme‐altered lesions in rat liver cirrhosis
Author(s) -
SAKAIDA ISAO,
OKITA KIWAMU
Publication year - 1995
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1111/j.1440-1746.1995.tb01801.x
Subject(s) - procollagen peptidase , cirrhosis , endocrinology , medicine , enzyme , choline , biochemistry , biology
A choline deficient l‐amino acid defined (CDAA) diet led to the development of liver cirrhosis in male Wistar rats after 16 weeks. A new prolyl 4‐hydroxylase inhibitor, 2,4‐pyridine dicarboxylic acid bis [(2‐methoxyethyl amide)] (HOE 077), prevented liver fibrosis in a dose‐dependent manner without a reduction in increased serum alanine aminotransferase and aspartate aminotransferase in parallel with a reduction in preneoplastic enzyme‐altered lesions stained with anti‐glutathione S‐transferase placental form antibody. HOE 077 reduced the increase in serum procollagen III peptide (PIIIP) in a dose‐dependent manner and in proportion to the reduction in mRNA expression of type III procollagen in the liver of rats fed a CDAA diet.